EP3787609A4 - Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine - Google Patents

Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine Download PDF

Info

Publication number: EP3787609A4
Authority: EP; European Patent Office
Prior art keywords: retinal; drug administration; eye drop; drop formulation; prolonged
Prior art date: 2018-05-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19796932.2A

Other languages

German (de)

English (en)

Other versions

EP3787609A1 (fr

Inventor

Vernon G. Wong

Glen T. HUANG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chibi Inc

Original Assignee

Chibi Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-01

Filing date

2019-05-01

Publication date

2022-01-05

2019-05-01 Application filed by Chibi Inc filed Critical Chibi Inc

2021-03-10 Publication of EP3787609A1 publication Critical patent/EP3787609A1/fr

2022-01-05 Publication of EP3787609A4 publication Critical patent/EP3787609A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP19796932.2A 2018-05-01 2019-05-01 Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine Withdrawn EP3787609A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862665273P	2018-05-01	2018-05-01
PCT/US2019/030290 WO2019213326A1 (fr)	2018-05-01	2019-05-01	Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine

Publications (2)

Publication Number	Publication Date
EP3787609A1 EP3787609A1 (fr)	2021-03-10
EP3787609A4 true EP3787609A4 (fr)	2022-01-05

Family

ID=68386777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19796932.2A Withdrawn EP3787609A4 (fr)	2018-05-01	2019-05-01	Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine

Country Status (9)

Country	Link
US (1)	US11497710B2 (fr)
EP (1)	EP3787609A4 (fr)
JP (1)	JP2021523222A (fr)
CN (1)	CN112423740A (fr)
AU (1)	AU2019262061A1 (fr)
BR (1)	BR112020022083A2 (fr)
CA (1)	CA3097926A1 (fr)
MX (1)	MX2020011535A (fr)
WO (1)	WO2019213326A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4652999A2 (fr)	2018-05-01	2025-11-26	Chibi, Inc.	Dépôt liquide pour l'administration prolongée non invasive d'agents à l' il

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130324481A1 (en) *	2004-10-01	2013-12-05	Ramscor, Inc.	Sustained release eye drop formulations
EP3272362A1 (fr) *	2015-03-18	2018-01-24	Santen Pharmaceutical Co., Ltd.	Composition pharmaceutique à libération prolongée

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869079A (en) *	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6331313B1 (en) *	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10030378A1 (de) *	2000-06-21	2002-03-14	Audit Inst For Medical Service	Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
US8425929B2 (en) *	2004-04-30	2013-04-23	Allergan, Inc.	Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
MXPA06014095A (es) *	2004-06-04	2007-08-07	Camurus Ab	Formulaciones de deposito de lipidos.
US8541413B2 (en)	2004-10-01	2013-09-24	Ramscor, Inc.	Sustained release eye drop formulations
US20080038316A1 (en)	2004-10-01	2008-02-14	Wong Vernon G	Conveniently implantable sustained release drug compositions
EP3173072A1 (fr) *	2004-10-01	2017-05-31	Ramscor, Inc.	Compositions de médicaments à libération prolongée parfaitement implantable
TWI376239B (en)	2006-02-01	2012-11-11	Andrew Xian Chen	Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
ES2402321T3 (es) *	2007-11-05	2013-04-30	Bausch & Lomb Incorporated	Materiales inmiscibles en agua como vehículos para el suministro de fármacos
CA2739658C (fr)	2008-10-09	2016-11-08	Ramscor, Inc.	Composition et methode pour traiter le syndrome de l'oeil sec
IT1393419B1 (it)	2009-03-19	2012-04-20	Medivis S R L	Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
CA2838646A1 (fr) *	2011-06-10	2013-04-25	Ramscor, Inc.	Formulations d'anti-oxydant a liberation prolongee, injectables ou implantables de maniere commode, pour des therapies de maladies oculaires ou de cancer
PL2717914T3 (pl)	2011-06-10	2020-05-18	Ramscor, Inc.	Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania
CN104093399B (zh) *	2011-12-05	2018-03-13	卡穆鲁斯公司	鲁棒性控释肽制剂
US20160339005A1 (en) *	2014-01-23	2016-11-24	Akebia Therapeutics, Inc.	Compositions and methods for treating ocular diseases
CA2950424C (fr)	2014-05-29	2023-03-14	Insys Pharma, Inc.	Formulations de cannabinoides stables
CN204581946U (zh) *	2015-04-25	2015-08-26	刘勇	一种眼药水存放装置
BR112018077259A2 (pt) *	2016-06-30	2019-06-18	Durect Corporation	formulações depot
EP4652999A2 (fr)	2018-05-01	2025-11-26	Chibi, Inc.	Dépôt liquide pour l'administration prolongée non invasive d'agents à l' il

2019
- 2019-05-01 MX MX2020011535A patent/MX2020011535A/es unknown
- 2019-05-01 AU AU2019262061A patent/AU2019262061A1/en not_active Abandoned
- 2019-05-01 WO PCT/US2019/030290 patent/WO2019213326A1/fr not_active Ceased
- 2019-05-01 EP EP19796932.2A patent/EP3787609A4/fr not_active Withdrawn
- 2019-05-01 BR BR112020022083-3A patent/BR112020022083A2/pt not_active Application Discontinuation
- 2019-05-01 JP JP2021510273A patent/JP2021523222A/ja active Pending
- 2019-05-01 CA CA3097926A patent/CA3097926A1/fr active Pending
- 2019-05-01 CN CN201980044701.6A patent/CN112423740A/zh active Pending
2020
- 2020-06-23 US US16/909,591 patent/US11497710B2/en active Active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130324481A1 (en) *	2004-10-01	2013-12-05	Ramscor, Inc.	Sustained release eye drop formulations
EP3272362A1 (fr) *	2015-03-18	2018-01-24	Santen Pharmaceutical Co., Ltd.	Composition pharmaceutique à libération prolongée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019213326A1 *

Also Published As

Publication number	Publication date
US11497710B2 (en)	2022-11-15
WO2019213326A1 (fr)	2019-11-07
AU2019262061A1 (en)	2020-11-26
EP3787609A1 (fr)	2021-03-10
US20200368153A1 (en)	2020-11-26
MX2020011535A (es)	2020-11-24
CA3097926A1 (fr)	2019-11-07
JP2021523222A (ja)	2021-09-02
BR112020022083A2 (pt)	2021-02-02
CN112423740A (zh)	2021-02-26

Publication	Publication Date	Title
EP3873442A4 (fr)	2022-08-10	Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés
EP3713530A4 (fr)	2021-08-18	Composition ophtalmique et dispositif d'administration associé
BR112016025997A8 (pt)	2021-07-06	compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
EP3829569A4 (fr)	2022-04-27	Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
EP3817747A4 (fr)	2022-07-06	Administration ciblée d'agents thérapeutiques à des adipocytes humains
EP3405215A4 (fr)	2019-08-28	Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
BR112018003870A2 (pt)	2018-09-25	construções cirúrgicas tubulares incluindo material auxiliar
MX2018010032A (es)	2019-03-11	Formulaciones de antagonista de il-6 y sus usos.
MA50905A (fr)	2020-09-23	Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3902525A4 (fr)	2022-09-28	Compositions pharmaceutiques ophtalmiques et procédés de traitement d'une maladie de surface oculaire
SG11201912110YA (en)	2020-01-30	Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
EP3672587A4 (fr)	2021-05-19	Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA50189A (fr)	2021-05-19	Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
MY199237A (en)	2023-10-22	Methods of treating ocular conditions
EP3405159A4 (fr)	2019-09-04	Traitement et prévention d'une maladie vasculaire rétinienne par photocoagulation
MA56220A (fr)	2022-04-20	Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
DK3749308T3 (da)	2024-01-22	Behandling af patienter med klassisk fabrys sygdom med migalastat
EP3921420A4 (fr)	2022-11-16	Compositions d'administration de médicament pour l'administration oculaire d'agents thérapeutiques et leurs méthodes d'utilisation
EP3362096A4 (fr)	2019-06-12	Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
MY194044A (en)	2022-11-09	Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
EP4291162A4 (fr)	2024-12-11	Procédés d'administration ophtalmique de roflumilast
EP3787609A4 (fr)	2022-01-05	Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine
IL259710A (en)	2018-07-31	Compositions and methods of treatment for mvid and related diseases
MA44286A (fr)	2019-01-09	Formulation pharmaceutique de cinéol et d'amoxicilline
EP3534932A4 (fr)	2020-09-09	Traitement de maladies associées à l'igfb3 et à son récepteur

Legal Events

Date	Code	Title	Description
2019-11-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-02-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-02-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-03-10	17P	Request for examination filed	Effective date: 20201015
2021-03-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-03-10	AX	Request for extension of the european patent	Extension state: BA ME
2021-08-04	DAV	Request for validation of the european patent (deleted)
2021-08-04	DAX	Request for extension of the european patent (deleted)
2022-01-05	A4	Supplementary search report drawn up and despatched	Effective date: 20211207
2022-01-05	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/00 20060101ALI20211201BHEP Ipc: A61K 47/18 20170101ALI20211201BHEP Ipc: A61K 47/10 20170101ALI20211201BHEP Ipc: A61K 31/07 20060101AFI20211201BHEP
2022-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2022-08-24	18W	Application withdrawn	Effective date: 20220720